Older adult oncology, version 2.2016: Featured updates to the NCCN guidelines

JNCCN Journal of the National Comprehensive Cancer Network

Volumn 14, Issue 11, 2016, Pages 1357-1370

  Van Der Walde, Noam ^a   Jagsi, Reshma ^b   Dotan, Efrat ^c   Baumgartner, Joel ^d   Browner, Ilene S ^e   Burhenn, Peggy ^f   Cohen, Harvey Jay ^g   Edil, Barish H ^h   Edwards, Beatrice ⁱ   Extermann, Martine ^j   Ganti, Apar Kishor P ^k   Gross, Cary ^l   Hubbard, Joleen ^m   Keating, Nancy L ⁿ   Korc Grodzicki, Beatriz ^o   McKoy, June M ^p   Medeiros, Bruno C ^q   Mrozek, Ewa ^r   O'Connor, Tracey ^s   Rugo, Hope S ^t   Rupper, Randall W ^u   Shepard, Dale ^v   Silliman, Rebecca A ^z   Stirewalt, Derek L ^w   Tew, William P ^o   Walter, Louise C ^t   Wildes, Tanya ^x   Bergman, Mary Anne ^y   Sundar, Hema ^y   Hurria, Arti ^f   more..

^a UNIVERSITY OF TENNESSEE HEALTH SCIENCE CENTER   (United States)

^b UNIVERSITY OF MICHIGAN COMPREHENSIVE CANCER CENTER   (United States)

^c FOX CHASE CANCER CENTER   (United States)

^d UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

^e JOHNS HOPKINS UNIVERSITY   (United States)

^f CITY OF HOPE NATIONAL MEDICAL CENTER   (United States)

^g DUKE CANCER INSTITUTE   (United States)

^h UNIVERSITY OF COLORADO   (United States)

ⁱ UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^j H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

^k UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

^l YALE CANCER CENTER   (United States)

^m MAYO CLINIC CANCER CENTER   (United States)

ⁿ DANA FARBER BRIGHAM AND WOMEN S CANCER CENTER   (United States)

^o MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^p NORTHWESTERN UNIVERSITY   (United States)

^q STANFORD CANCER INSTITUTE   (United States)

^r OHIO STATE UNIVERSITY   (United States)

^s ROSWELL PARK CANCER INSTITUTE   (United States)

^t UNIVERSITY OF CALIFORNIA   (United States)

^u UNIVERSITY OF UTAH   (United States)

^v UNIVERSITY HOSPITALS OF CLEVELAND   (United States)

^w SEATTLE CANCER CARE ALLIANCE   (United States)

^x BARNES JEWISH HOSPITAL   (United States)

^y National Comprehensive Cancer Network   (United States)

^z NONE

more..

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; AGED; CANCER EPIDEMIOLOGY; CAUSE OF DEATH; CHEMOTHERAPY; CLINICAL STUDY; CLINICAL TRIAL; DRUG THERAPY; HUMAN; MOLECULARLY TARGETED THERAPY; ONCOLOGY; ORGANS AT RISK; PRACTICE GUIDELINE; RADIOTHERAPY; SURGERY; VERY ELDERLY;

AGED; AGED, 80 AND OVER; HUMANS; MEDICAL ONCOLOGY;

EID: 84994626854     PISSN: 15401405     EISSN: 15401413     Source Type: Journal    
DOI: 10.6004/jnccn.2016.0146     Document Type: Review

References (57)

1. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2016. CA Cancer J Clin 2016;66:7-30.
2. Altekruse SF KC, Krapcho M, Neyman N, et al, eds. SEER Cancer Statistics Review, 1975-2007: National Cancer Institute. Bethesda, MD, based on November 2009 SEER data submission, posted to the SEER web site, 2010. Available at: http://seer.cancer.gov/csr/1975-2007/. Accessed October 12, 2016.
3. Smith BD, Smith GL, Hurria A, et al. Future of cancer incidence in the United States: burdens upon an aging, changing nation. J Clin Oncol 2009;27:2758-2765.
4. Talarico L, Chen G, Pazdur R. Enrollment of elderly patients in clinical trials for cancer drug registration: a 7-year experience by the US Food and Drug Administration. J Clin Oncol 2004;22:4626-4631.
5. Balducci L. Management of cancer in the elderly. Oncology (Williston Park) 2006;20:135-143.
6. Saltzstein SL, Behling CA. 5- and 10-year survival in cancer patients aged 90 and older: a study of 37,318 patients from SEER. J Surg Oncol 2002;81:113-116; discussion 117.
7. Extermann M. Management issues for elderly patients with breast cancer. Curr Treat Options Oncol 2004;5:161-169.
8. Zachariah B, Balducci L. Radiation therapy of the older patient. Hematol Oncol Clin North Am 2000;14:131-167.
9. Smith GL, Smith BD. Radiation treatment in older patients: a framework for clinical decision making. J Clin Oncol 2014;32:2669-2678.
10. Zachariah B, Balducci L, Venkattaramanabalaji G V, et al. Radiotherapy for cancer patients aged 80 and older: a study of effectiveness and side effects. Int J Radiat Oncol Biol Phys 1997;39:1125-1129.
11. Mitsuhashi N, Hayakawa K, Yamakawa M, et al. Cancer in patients aged 90 years or older: radiation therapy. Radiology 1999;211:829-833.
12. Wasil T, Lichtman SM, Gupta V, Rush S. Radiation therapy in cancer patients 80 years of age and older. Am J Clin Oncol 2000;23:526-530.
13. Kunkler IH, Audisio R, Belkacemi Y, et al. Review of current best practice and priorities for research in radiation oncology for elderly patients with cancer: the International Society of Geriatric Oncology (SIOG) task force. Ann Oncol 2014;25:2134-2146.
14. Donato V, Valeriani M, Zurlo A. Short course radiation therapy for elderly cancer patients. Evidences from the literature review. Crit Rev Oncol Hematol 2003;45:305-311.
15. Hughes KS, Schnaper LA, Berry D, et al. Lumpectomy plus tamoxifen with or without irradiation in women 70 years of age or older with early breast cancer. N Engl J Med 2004;351:971-977.
16. Hughes KS, Schnaper LA, Bellon JR, et al. Lumpectomy plus tamoxifen with or without irradiation in women age 70 years or older with early breast cancer: long-term follow-up of CALGB 9343. J Clin Oncol 2013;31:2382-2387.
17. Kunkler IH, Williams LJ, Jack WJ, et al. Breast-conserving surgery with or without irradiation in women aged 65 years or older with early breast cancer (PRIME II): a randomised controlled trial. Lancet Oncol 2015;16:266-273.
18. Stupp R, Hegi M, Mason W, et al. Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomized phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet Oncol 2009;10:459-466.
19. Perry JR, Laperriere N, O'Callaghan CJ, et al. A phase III randomized controlled trial of short-course radiotherapy with or without concomitant and adjuvant temozolomide in elderly patients with glioblastoma (CCTG CE.6, EORTC 26062-22061, TROG 08.02, NCT00482677) [abstract]. J Clin Oncol 2016;34(18 Suppl):Abstract LBA2.
20. Minniti G, Lanzetta G, Scaringi C, et al. Phase II study of short-course radiotherapy plus concomitant and adjuvant temozolomide in elderly patients with glioblastoma. Int J Radiat Oncol Biol Phys 2012;83:93-99.
21. Behm T, Horowski A, Schneider S, et al. Concomitant and adjuvant temozolomide of newly diagnosed glioblastoma in elderly patients. Clin Neurol Neurosurg 2013;115:2142-2146.
22. Minniti G, Scaringi C, Lanzetta G, et al. Standard (60 Gy) or short-course (40 Gy) irradiation plus concomitant and adjuvant temozolomide for elderly patients with glioblastoma: a propensity-matched analysis. Int J Radiat Oncol Biol Phys 2015;91:109-115.
23. Arvold ND, Tanguturi SK, Aizer AA, et al. Hypofractionated versus standard radiation therapy with or without temozolomide for older glioblastoma patients. Int J Radiat Oncol Biol Phys 2015;92:384-389.
24. Roa W, Brasher PM, Bauman G, et al. Abbreviated course of radiation therapy in older patients with glioblastoma multiforme: a prospective randomized trial. J Clin Oncol 2004;22:1583-1588.
25. Keime-Guibert F, Chinot O, Taillandier L, et al. Radiotherapy for glioblastoma in the elderly. N Engl J Med 2007;356:1527-1535.
26. Minniti G, Salvati M, Arcella A, et al. Correlation between O6-methylguanine-DNA methyltransferase and survival in elderly patients with glioblastoma treated with radiotherapy plus concomitant and adjuvant temozolomide. J Neurooncol 2011;102:311-316.
27. Wick W, Platten M, Meisner C, et al. Temozolomide chemotherapy alone versus radiotherapy alone for malignant astrocytoma in the elderly: the NOA-08 randomised, phase 3 trial. Lancet Oncol 2012;13:707-715.
28. Malmstrom A, Gronberg BH, Marosi C, et al. Temozolomide versus standard 6-week radiotherapy versus hypofractionated radiotherapy in patients older than 60 years with glioblastoma: the Nordic randomised, phase 3 trial. Lancet Oncol 2012;13:916-926.
29. Kim J, Ko ME, Nelson RA, et al. Increasing age and survival after orthotopic liver transplantation for patients with hepatocellular cancer. J Am Coll Surg 2014;218:431-438.
30. Faber W, Stockmann M, Schirmer C, et al. Significant impact of patient age on outcome after liver resection for HCC in cirrhosis. Eur J Surg Oncol 2014;40:208-213.
31. Fan HL, Hsieh CB, Chang WC, et al. Advanced age is not a contraindication for liver resection in cases of large hepatocellular carcinoma. Eur J Surg Oncol 2014;40:214-219.
32. Thornton RH, Covey A, Petre EN, et al. A comparison of outcomes from treating hepatocellular carcinoma by hepatic artery embolization in patients younger or older than 70 years. Cancer 2009;115:5000-5006.
33. Mirici-Cappa F, Gramenzi A, Santi V, et al. Treatments for hepatocellular carcinoma in elderly patients are as effective as in younger patients: a 20-year multicentre experience. Gut 2010;59:387-396.
34. Kozyreva ON, Chi D, Clark J W, et al. A multicenter retrospective study on clinical characteristics, treatment patterns, and outcome in elderly patients with hepatocellular carcinoma. Oncologist 2011;16:310-318.
35. Ozenne V, Bouattour M, Goutte N, et al. Prospective evaluation of the management of hepatocellular carcinoma in the elderly. Dig Liver Dis 2011;43:1001-1005.
36. Peng ZW, Liu FR, Ye S, et al. Radiofrequency ablation versus open hepatic resection for elderly patients (> 65 years) with very early or early hepatocellular carcinoma. Cancer 2013;119:3812-3820.
37. Bujold A, Massey CA, Kim JJ, et al. Sequential phase I and II trials of stereotactic body radiotherapy for locally advanced hepatocellular carcinoma. J Clin Oncol 2013;31:1631-1639.
38. Tse RV, Hawkins M, Lockwood G, et al. Phase I study of individualized stereotactic body radiotherapy for hepatocellular carcinoma and intrahepatic cholangiocarcinoma. J Clin Oncol 2008;26:657-664.
39. Cardenes HR, Price TR, Perkins SM, et al. Phase I feasibility trial of stereotactic body radiation therapy for primary hepatocellular carcinoma. Clin Transl Oncol 2010;12:218-225.
40. Andolino DL, Johnson CS, Maluccio M, et al. Stereotactic body radiotherapy for primary hepatocellular carcinoma. Int J Radiat Oncol Biol Phys 2011;81:e447-453.
41. Sanuki N, Takeda A, Oku Y, et al. Stereotactic body radiotherapy for small hepatocellular carcinoma: a retrospective outcome analysis in 185 patients. Acta Oncol 2014;53:399-404.
42. Palma D, Visser O, Lagerwaard FJ, et al. Treatment of stage I NSCLC in elderly patients: a population-based matched-pair comparison of stereotactic radiotherapy versus surgery. Radiother Oncol 2011;101:240-244.
43. Samuels MA, Kandula S, Koru-Sengul T, et al. Stereotactic body radiotherapy in patients with stage I non-small-cell lung cancer aged 75 years and older: retrospective results from a multicenter consortium. Clin Lung Cancer 2013;14:446-451.
44. Chang JY, Senan S, Paul MA, et al. Stereotactic ablative radiotherapy versus lobectomy for operable stage I non-small-cell lung cancer: a pooled analysis of two randomised trials. Lancet Oncol 2015;16:630-637.
45. Schild SE, Stella PJ, Geyer SM, et al. The outcome of combined-modality therapy for stage III non-small-cell lung cancer in the elderly. J Clin Oncol 2003;21:3201-3206.
46. Atagi S, Kawahara M, Yokoyama A, et al. Thoracic radiotherapy with or without daily low-dose carboplatin in elderly patients with non-small-cell lung cancer: a randomised, controlled, phase 3 trial by the Japan Clinical Oncology Group (JCOG0301). Lancet Oncol 2012;13:671-678.
47. Rule WG, Foster NR, Meyers J P, et al. Prophylactic cranial irradiation in elderly patients with small cell lung cancer: findings from a North Central Cancer Treatment Group pooled analysis. J Geriatr Oncol 2015;6:119-126.
48. Wolfson AH, Bae K, Komaki R, et al. Primary analysis of a phase II randomized trial Radiation Therapy Oncology Group (RTOG) 0212: impact of different total doses and schedules of prophylactic cranial irradiation on chronic neurotoxicity and quality of life for patients with limited-disease small-cell lung cancer. Int J Radiat Oncol Biol Phys 2011;81:77-84.
49. Le Pechoux C, Laplanche A, Faivre-Finn C, et al. Clinical neurological outcome and quality of life among patients with limited small-cell cancer treated with two different doses of prophylactic cranial irradiation in the intergroup phase III trial (PCI99-01, EORTC 22003-08004, RTOG 0212 and IFCT 99-01). Ann Oncol 2011;22:1154-1163.
50. Shahinian VB, Kuo YF, Freeman JL, Goodwin JS. Risk of fracture after androgen deprivation for prostate cancer. N Engl J Med 2005;352:154-164.
51. Keating NL, O'Malley AJ, Smith MR. Diabetes and cardiovascular disease during androgen deprivation therapy for prostate cancer. J Clin Oncol 2006;24:4448-4456.
52. Ehdaie B, Atoria CL, Gupta A, et al. Androgen deprivation and thromboembolic events in men with prostate cancer. Cancer 2012;118:3397-3406.
53. D'Amico AV, Chen MH, Renshaw AA, et al. Androgen suppression and radiation vs radiation alone for prostate cancer: a randomized trial. JAMA 2008;299:289-295.
54. Roach M, Bae K, Speight J, et al. Short-term neoadjuvant androgen deprivation therapy and external-beam radiotherapy for locally advanced prostate cancer: long-term results of RTOG 8610. J Clin Oncol 2008;26:585-591.
55. Denham JW, Steigler A, Lamb DS, et al. Short-term neoadjuvant androgen deprivation and radiotherapy for locally advanced prostate cancer: 10-year data from the TROG 96.01 randomised trial. Lancet Oncol 2011;12:451-459.
56. Jones CU, Hunt D, McGowan DG, et al. Radiotherapy and short-term androgen deprivation for localized prostate cancer. N Engl J Med 2011;365:107-118.
57. D'Amico AV, Renshaw AA, Loffredo B, Chen MH. Duration of testosterone suppression and the risk of death from prostate cancer in men treated using radiation and 6 months of hormone therapy. Cancer 2007;110:1723-1728.